SMIP 004

Biological Activity

SMIP 004 is an SKP2 (S-phase kinase-associated protein 2) inhibitor. Upregulates p27 and activates the unfolded protein response (UPR) in LNCaP prostate cancer cells overexpressing SKP2. Also induces oxidative stress. Induces proteasomal degradation of cyclin D1 and acts as CDK2 inhibitor. Arrests cell cycle in G₁ phase and induces apoptosis in prostate cancer cells, but not normal cells in vitro. Inhibits growth of breast and prostate cancer xenografts in mice. Also induces autophagy and reduces replication of MERS-CoV in VeroB4 cells.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
   Rico-Bautista et al.
   BMC Biol., 2010;8:153
2. Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling.
   Rico-Bautista et al.
   Oncotarget, 2013;4:1212
3. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection.
   Gassen et al.
   Nat.Commun., 2019;10:5770

Product Datasheets